Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

BioAge Labs is having its initial public offering today. The drug developer’s signature product, Azelaprag, isn’t yet on sale ...

A well-known collaborator with Eli Lilly – BioAge Labs is focusing on developing an anti-obesity drug for the elderly "by targeting the biology of human ageing", the biopharmaceutical start-up said.

Kristen Fortney, cofounder and CEO of BioAge Labs. BioAge's main oral, small-molecule drug candidate, azelaprag, has been tested in 265 people across eight Phase I clinical trials. In preclinical ...

Obesity-drug developer BioAge Labs Inc. held on to a slim gain at the closing bell and natural-gas producer BKV Corp. ended flat Thursday, the day the two initial public offerings debuted.

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%. The expansion of the listing reflects the massive ...

"Our preclinical data highlight the potential of azelaprag as a novel oral therapy for obesity," said Kristen Fortney, Ph.D., CEO and co-founder of BioAge. “Our two presentations provide evidence ...

Texas-based Barnett Shale driller BKV Inc. priced below the estimated range, while obesity-drug developer BioAge Labs Inc. priced midrange ahead of their first day of trading on Thursday.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead ...

Kristen Fortney, cofounder and CEO of BioAge Labs. From the San Francisco Business Times. BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs ...

RICHMOND, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases ...